Sricharan Bandhakavi, T. Berkelman, A. Harbers, Sara Heitkamp and Michael Early
Scientific Tracks Abstracts: J Bioanal Biomed
Biologics and biosimilars can contain traces of proteins from the host cell line, which need to be minimized to prevent adverse immune reactions. The presence of host-cell proteins (HCP) is usually assayed by ELISA using a polyclonal antibody mixture raised against a population of proteins derived from the host cell background. This antibody should recognize as high a proportion as possible of the potential HCP?s in a given sample. A recommended method for evaluating the assay involves two-dimensional electrophoretic separation followed by Western blotting. Although this method allows a straightforward determination of the range of reactivity of the antibody mixture, adoption of this methodology has been hindered by the perceived lack of sensitivity, lack of reproducibility and overall laborious nature of the 2-D electrophoresis and blotting workflow. Tools that simplify, standardize and accelerate 2-D electrophoresis and blotting have become available. Advanced electrophoresis and blotting instrumentation, stable and reproducible pre-cast gels, next-generation imaging and image analysis software all allow this assay to be performed in a reproducible manner in a relatively short time. We have undertaken to demonstrate this using a commercial anti-HCP antibody and samples derived from Chinese Hamster Ovary (CHO) cells. The 2 D electrophoresis procedure resulted in highly reproducible spot patterns and entire procedure was completed in less than two days. The software used (PDQuest) enabled the straightforward generation of percent coverage values for the antibody when used to probe both CHO cell lysate and CHO cell secreted protein.
Sricharan Bandhakavi is Global Product Manager-Collaborations & Applications within the Laboratory Separations Division of Bio-Rad Laboratories. He fosters collaborations between Bio-Rad and scientists world-wide on enabling technologies for protein separation, analysis/detection, and their biological/pharmaceutical applications. Sri has more than 10 years of R&D experience in academic and industry settings, authored more than 20 peer-reviewed papers, and contributed to multiple patent applications.
Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report